Biologics

Pfizer sBLA Approved for Panzyga

FDA has approved a Pfizer supplemental BLA for Panzyga (immune globulin intravenous [human] – ifas 10% liquid preparation) to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare peripheral nerve neurological disease. Approval was based on data from a Phase 3 study in 142 patients diagnosed with CIDP. The primary endpoint was met with 80% of patients in the study achieving a favorable Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, according to the company. The most common adverse reactions across all dosing arms were headache (15%), fever (14%), dermatitis (10%), and blood pressure increase (8%). Panzyga was approved in 2018 for treating primary immunodeficiency in patients two years of age and older and chronic immune thrombocytopenia in adults.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome